» Articles » PMID: 38003845

The Next Frontier in Sarcoma Care: Digital Health, AI, and the Quest for Precision Medicine

Overview
Journal J Pers Med
Date 2023 Nov 25
PMID 38003845
Authors
Affiliations
Soon will be listed here.
Abstract

The landscape of sarcoma care is on the cusp of a transformative era, spurred by the convergence of digital health and artificial intelligence (AI). This perspectives article explores the multifaceted opportunities and challenges in leveraging these technologies for value-based, precision sarcoma care. We delineate the current state-of-the-art methodologies and technologies in sarcoma care and outline their practical implications for healthcare providers, administrators, and policymakers. The article also addresses the limitations of AI and digital health platforms, emphasizing the need for high-quality data and ethical considerations. We delineate the promise held by the synergy of digital health platforms and AI algorithms in enhancing data-driven decision-making, outcome analytics, and personalized treatment planning. The concept of a sarcoma digital twin serves as an illustrative paradigm for this integration, offering a comprehensive, patient-centric view of the healthcare journey. The paper concludes with proposals for future research aimed at advancing the field, including the need for randomized controlled trials or target trial emulations and studies focusing on ethical and economic aspects. While the road to this transformative care is laden with ethical, regulatory, and practical challenges, we believe that the potential benefits far outweigh the obstacles. We conclude with a call to action for multidisciplinary collaboration and systemic adoption of these technologies, underscoring the urgency to act now for the future betterment of sarcoma care and healthcare at large.

Citing Articles

Ultrahypofractionated Versus Normofractionated Preoperative Radiotherapy for Soft Tissue Sarcoma: A Multicenter, Prospective Real-World-Time Phase 2 Clinical Trial.

Heesen P, Di Lonardo M, Ciobanu-Caraus O, Schelling G, Zwahlen D, Bode-Lesniewska B Cancers (Basel). 2024; 16(23).

PMID: 39682249 PMC: 11640059. DOI: 10.3390/cancers16234063.


Beyond the sarcoma center: establishing the Sarcoma HASM network-a Hub and Spoke Model network for global integrated and precision care.

Fuchs B, Gronchi A ESMO Open. 2024; 9(12):103734.

PMID: 39642636 PMC: 11666932. DOI: 10.1016/j.esmoop.2024.103734.


From Data Integration to Precision Medicine: A Value-Based Healthcare Approach for Sarcoma Care.

Fuchs B, Heesen P J Clin Med. 2024; 13(21).

PMID: 39518639 PMC: 11546467. DOI: 10.3390/jcm13216500.


Real-World-Time Data and RCT Synergy: Advancing Personalized Medicine and Sarcoma Care through Digital Innovation.

Heesen P, Schelling G, Birbaumer M, Jager R, Bode B, Studer G Cancers (Basel). 2024; 16(14).

PMID: 39061155 PMC: 11274374. DOI: 10.3390/cancers16142516.


Joint Expedition: Exploring the Intersection of Digital Health and AI in Precision Medicine with Team Integration.

Giansanti D J Pers Med. 2024; 14(4).

PMID: 38673015 PMC: 11051462. DOI: 10.3390/jpm14040388.


References
1.
Porter M . A strategy for health care reform--toward a value-based system. N Engl J Med. 2009; 361(2):109-12. DOI: 10.1056/NEJMp0904131. View

2.
Kubicek P, Cesne A, Lervat C, Toulmonde M, Chevreau C, Duffaud F . Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC. BMC Cancer. 2023; 23(1):69. PMC: 9854049. DOI: 10.1186/s12885-023-10556-4. View

3.
Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S . Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2018; 2(4):230-243. PMC: 5829945. DOI: 10.1136/svn-2017-000101. View

4.
Hoeben A, Joosten E, van den Beuken-van Everdingen M . Personalized Medicine: Recent Progress in Cancer Therapy. Cancers (Basel). 2021; 13(2). PMC: 7826530. DOI: 10.3390/cancers13020242. View

5.
Blay J, Penel N, Gouin F, Le Cesne A, Toulmonde M . Improving at a nationwide level the management of patients with sarcomas with an expert network. Ann Oncol. 2022; 33(6):659-661. DOI: 10.1016/j.annonc.2022.02.221. View